Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV002417471 | SCV002725964 | likely pathogenic | Hereditary cancer-predisposing syndrome | 2021-09-01 | criteria provided, single submitter | clinical testing | The c.211_263+3141del3194 gross deletion spans a portion of coding exon 3 into intron 3 in the RAD51D gene. This deletion encompasses the native splice donor site. In silico splice site analysis predicts that this alteration will weaken the native splice donor site; however direct evidence is insufficient at this time (Ambry internal data). Alterations that disrupt the canonical splice site are expected to cause aberrant splicing, resulting in an abnormal protein or a transcript that is subject to nonsense-mediated mRNA decay. As such, this alteration is classified as likely pathogenic. |